Gilead Sciences, Inc. (GILD) operating KPIs
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)
Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%
Gilead Sciences indefinite-lived IPR&D — Trodelvy NSCLC (impaired in FY2024, $M) ($M)
Form 10-Q / 10-K Note 9
Latest, Q1 2026
1,750
Period ended Mar 31, 2026
Change on a year earlier
-2.8%
1,800 in Q1 2025
History
8 quarters
Since Q4 2023
Sources
7
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Indefinite-lived IPR&D — Trodelvy NSCLC (impaired in FY2024, $M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q1 2026 | Mar 31, 2026 | 1,750 | -2.8% | Form 10-Q (filed 2026-05-07) ↗ |
| Q4 2025 | Dec 31, 2025 | 1,750 | 0.0% | Form 10-K (filed 2026-02-24) ↗ |
| Q3 2025 | Sep 30, 2025 | 1,750 | -2.8% | Form 10-Q (filed 2025-11-07) ↗ |
| Q2 2025 | Jun 30, 2025 | 1,750 | – | Form 10-Q (filed 2025-08-07) ↗ |
| Q1 2025 | Mar 31, 2025 | 1,800 | – | Form 10-Q (filed 2025-05-07) ↗ |
| Q4 2024 | Dec 31, 2024 | 1,750 | -70.3% | Form 10-K (filed 2026-02-24) ↗ |
| Q3 2024 | Sep 30, 2024 | 1,800 | – | Form 10-Q (filed 2024-11-12) ↗ |
| Q4 2023 | Dec 31, 2023 | 5,900 | – | Form 10-K (filed 2025-02-28) ↗ |
Cite this data
StockData. (2026). Gilead Sciences Indefinite-lived IPR&D — Trodelvy NSCLC (impaired in FY2024, $M) ($M), quarterly Q4 2023–Q1 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/intang_iprd_nsclc
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.